23 min

Giving genes the silent treatment, with Dicerna Pharmaceuticals One Step Ahead by Lyxor ETF

    • Entrepreneurship

In this episode of One Step Ahead, Douglas Fambrough, Ph.D., President and CEO at Dicerna Pharmaceuticals, talks us through “RNA interference,” an innovative technique that can target and silence certain disease-causing genes. From kidney-related disease to neurological disorders – and potentially even alcohol use disorder – he asserts that gene-based medicines have the potential to be a safe and effective approach to treating disease. According to Dr. Fambrough, we’re at the early stages of a “big bang” for gene-based medicine, and RNAi is just one of many disruptive technologies set to change the future of healthcare.

This episode was presented by Libby Potter.

See omnystudio.com/listener for privacy information.

In this episode of One Step Ahead, Douglas Fambrough, Ph.D., President and CEO at Dicerna Pharmaceuticals, talks us through “RNA interference,” an innovative technique that can target and silence certain disease-causing genes. From kidney-related disease to neurological disorders – and potentially even alcohol use disorder – he asserts that gene-based medicines have the potential to be a safe and effective approach to treating disease. According to Dr. Fambrough, we’re at the early stages of a “big bang” for gene-based medicine, and RNAi is just one of many disruptive technologies set to change the future of healthcare.

This episode was presented by Libby Potter.

See omnystudio.com/listener for privacy information.

23 min